Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

Oncologist - United States
doi 10.1634/theoncologist.2010-0098
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy

Case Reports in Infectious Diseases
2016English

Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy

Frontiers in Neurology
Neurology
2020English

Progressive Multifocal Leukoencephalopathy

Journal of Multiple Sclerosis
2013English

Progressive Multifocal Leukoencephalopathy

Neurology
Neurology
2002English

Treatment of Progressive Multifocal Leukoencephalopathy With Interleukin 7

JAMA Neurology
Neurology
2014English

Progressive Multifocal Leukoencephalopathy: Current Insights

Degenerative Neurological and Neuromuscular Disease
2019English

Treatment-Related Progressive Multifocal Leukoencephalopathy: Current Understanding and Future Steps

Therapeutic Advances in Drug Safety
Pharmacology
2012English

Incidence and Risk Factors for Progressive Multifocal Leukoencephalopathy Among Patients With Selected Rheumatic Diseases

Arthritis Care and Research
Rheumatology
2012English

Neuropharmacokinetic Heterogeneity of Mefloquine in the Treatment of Progressive Multifocal Leukoencephalopathy

Internal Medicine
Internal MedicineMedicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy